バイオテクノロジー受託製造市場の評価：プラットフォームタイプ・製品タイプ・用途・治療領域・地域別の機会および予測 (2017～2031年)

世界のバイオテクノロジー受託製造の市場規模は、2023年の176億9,000万米ドルから、2024年から2031年の予測期間中は8.5%のCAGRで推移し、2031年には339億7,000万米ドルの規模に成長すると予測されています。

バイオテクノロジー受託製造の市場は、バイオ医薬品の需要拡大や細胞・遺伝子治療技術の進歩といった促進要因の影響を受けて成長すると予想されます。バイオ医薬品はその性質上複雑であり、専門的な製造設備が必要とされるため、製薬企業にとって管理は容易ではありません。このような状況で、製薬会社は市場の要求に応えるため、独自の専門知識と製造能力を持つ製造受託機関を雇っています。新規細胞・遺伝子治療の応用分野と需要が拡大していることも市場の拡大を大きく促しています。さらに製造技術の進歩や製薬会社と生物製剤受託製造業者間の協力関係も市場成長の主な原動力となっています。しかし一方で、生物製剤は複雑であり、専門的な施設や設備のニーズが絶えず進化していることが、市場成長の大きな課題となっています。また、規制の複雑さや制限が市場成長の抑制要因となっています。これらの課題と抑制要因にもかかわらず、市場は今後飛躍的に成長すると予想されています。

高まるバイオ医薬品需要

バイオ医薬品に対する世界の需要は、慢性疾患の蔓延、高齢者人口の増加、バイオ医薬品への効率的かつ容易なアクセスに対する意識の高まりにより、急速に拡大しています。また、遺伝子ベースのバイオ医薬品など、さまざまな疾患を治療するための先進的なバイオ医薬品に対する需要の高まりも、市場の成長を後押ししています。市場がバイオ医薬品需要の急増を目の当たりにする中で、バイオテクノロジー受託製造のニーズはさらに高まる見通しです。メーカー各社は、市場ニーズへの対応を強化するため、常に新しい製品の発売やサービスの拡充に取り組んでいます。

製造技術の進歩

製造技術はバイオテクノロジー受託製造に変化をもたらし、効率の改善、カスタマイズの拡大、コミュニケーションの強化につながっています。自動化、柔軟性、サプライチェーンマネジメントの強化により、製造工程はより効率的、コスト効率的、信頼性の高いものとなっています。こうした進歩により、受託製造業者は高品質の製品を大量に生産できるようになり、市場の需要拡大に対応できるようになっています。個別化医薬品とバイオシミラーの進展も市場の牽引力をさらに高めています。

哺乳動物ベースのプラットフォームの優位性

哺乳動物細胞ベースのバイオテクノロジーは、免疫疾患の治療に不可欠な高品質のタンパク質を作り出します。これらの製品は、疾患に対する抗体治療法の開発において主な役割を担っており、精度の向上や副作用の少なさなど、旧来の方法にはない利点があります。

当レポートでは、世界のバイオテクノロジー受託製造の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のバイオテクノロジー受託製造市場の展望

• 市場規模・予測
• プラットフォームタイプ別
  • 哺乳類ベース
  • 微生物ベース
• 製品タイプ別
  • モノクローナル抗体
  • 組換えタンパク質
  • ワクチン
  • インスリン
  • 成長因子
  • インターフェロン
  • その他
• 用途別
  • 臨床
  • 商用
• 治療領域別
  • 自己免疫疾患
  • 腫瘍
  • 代謝性疾患
  • 眼科
  • 心血管疾患
  • 感染症
  • 神経内科
  • 呼吸器疾患
  • その他
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別の市場シェア

第5章 世界のバイオテクノロジー受託製造市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング

• プラットフォームタイプ別
• 製品タイプ別
• 用途別
• 治療領域別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

• 特許の情勢
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析（主要企業）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Catalent Inc.
• Lonza Group Ag
• Patheon N.V. (Thermo Fisher Scientific Inc.)
• Abzena Plc.
• Sandoz International GmbH (Novartis AG)
• Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
• Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
• AbbVie Contract Manufacturing (AbbVie Inc.)
• Samsung Biologics Co. Ltd.
• Pfizer Centre Source Ltd (Pfizer Inc.)

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 2.Global Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 3.Global Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 4.Global Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 5.Global Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 6.Global Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 7.Global Biotechnology Contract Manufacturing Market Share (%), By Region, 2017-2031F
• Figure 8.North America Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 9.North America Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 10.North America Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 11.North America Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 12.North America Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 13.North America Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 14.North America Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
• Figure 15.United States Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 16.United States Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 17.United States Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 18.United States Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 19.United States Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 20.United States Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 21.Canada Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 22.Canada Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 23.Canada Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 24.Canada Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 25.Canada Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 26.Canada Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 27.Mexico Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 28.Mexico Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 29.Mexico Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 30.Mexico Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 31.Mexico Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 32.Mexico Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 33.Europe Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 34.Europe Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 35.Europe Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 36.Europe Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 37.Europe Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 38.Europe Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 39.Europe Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
• Figure 40.Germany Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 41.Germany Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 42.Germany Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 43.Germany Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 44.Germany Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 45.Germany Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 46.France Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 47.France Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 48.France Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 49.France Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 50.France Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 51.France Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 52.Italy Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 53.Italy Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 54.Italy Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 55.Italy Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 56.Italy Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 57.Italy Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 58.United Kingdom Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 59.United Kingdom Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 60.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 61.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 62.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 63.United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 64.Russia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 65.Russia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 66.Russia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 67.Russia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 68.Russia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 69.Russia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 70.Netherlands Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 71.Netherlands Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 72.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 73.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 74.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 75.Netherlands Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 76.Spain Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 77.Spain Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 78.Spain Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 79.Spain Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 80.Spain Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 81.Spain Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 82.Turkey Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 83.Turkey Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 84.Turkey Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 85.Turkey Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 86.Turkey Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 87.Turkey Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 88.Poland Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 89.Poland Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 90.Poland Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 91.Poland Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 92.Poland Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 93.Poland Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 94.South America Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 95.South America Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 96.South America Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 97.South America Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 98.South America Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 99.South America Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 100.South America Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
• Figure 101.Brazil Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 102.Brazil Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 103.Brazil Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 104.Brazil Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 105.Brazil Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 106.Brazil Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 107.Argentina Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 108.Argentina Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 109.Argentina Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 110.Argentina Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 111.Argentina Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 112.Argentina Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 113.Asia-Pacific Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 114.Asia-Pacific Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 115.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 116.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 117.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 118.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 119.Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
• Figure 120.India Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 121.India Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 122.India Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 123.India Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 124.India Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 125.India Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 126.China Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 127.China Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 128.China Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 129.China Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 130.China Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 131.China Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 132.Japan Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 133.Japan Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 134.Japan Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 135.Japan Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 136.Japan Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 137.Japan Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 138.Australia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 139.Australia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 140.Australia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 141.Australia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 142.Australia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 143.Australia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 144.Vietnam Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 145.Vietnam Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 146.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 147.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 148.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 149.Vietnam Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 150.South Korea Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 151.South Korea Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 152.South Korea Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 153.South Korea Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 154.South Korea Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 155.South Korea Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 156.Indonesia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 157.Indonesia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 158.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 159.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 160.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 161.Indonesia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 162.Philippines Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 163.Philippines Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 164.Philippines Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 165.Philippines Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 166.Philippines Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 167.Philippines Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 168.Middle East & Africa Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 169.Middle East & Africa Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 170.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 171.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 172.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 173.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 174.Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
• Figure 175.Saudi Arabia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 176.Saudi Arabia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 177.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 178.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 179.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 180.Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 181.UAE Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 182.UAE Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 183.UAE Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 184.UAE Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 185.UAE Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 186.UAE Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 187.South Africa Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
• Figure 188.South Africa Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
• Figure 189.South Africa Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
• Figure 190.South Africa Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
• Figure 191.South Africa Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
• Figure 192.South Africa Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
• Figure 193.By Platform Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195.By Application Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196.By Therapeutic Area Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global biotechnology contract manufacturing market is projected to witness a CAGR of 8.5% during the forecast period 2024-2031, growing from USD 17.69 billion in 2023 to USD 33.97 billion in 2031. The biotechnology contract manufacturing market is expected to thrive under the influence of driving factors like growing demand for biopharmaceuticals and technical advancements in cell and gene therapies. Biopharmaceutical products are complex in nature and require a specialized manufacturing setup, which is not easy to manage for pharmaceutical firms. In such situations, pharmaceutical companies hire contract manufacturing organizations with exclusive expertise and manufacturing capabilities to cater to the market requirements. The growing application areas and demand for novel cell and gene therapy have significantly induced market expansion. Advancements in manufacturing technologies and collaborations between pharmaceutical companies and biologics contract manufacturers are some other major driving forces for market growth. However, the complexities in the biologics and constantly evolving needs of specialized facilities and equipment are the major growth challenges for the market. Additionally, regulatory complications and restrictions pose restraints on market growth. With regularly evolving technology, the contract manufacturers need to stay updated, which hinders the expansion of key players. Despite all the challenges and restraints, the market is expected to grow exponentially in the future.

In October 2023, with the introduction of Expert'Biome CDMO by Lallemand, the company is bolstering its strategic position in the microbiome space through contract development and production operations. By providing extensive services in the healthcare sector, Lallemand Health Solutions hopes to assist partners in the creation of next-generation strains through Expert'Biome. These services include medicine manufacturing, bioprocess scaling, strain research and development, and other production procedures.

Growing Demand for Biopharmaceuticals

The global demand for biopharmaceuticals is growing rapidly due to the increasing prevalence of chronic diseases, a rising elderly population, and the growing awareness of efficiency and easy access to biopharmaceuticals. The increasing demand for advanced biologic drugs, such as gene-based biopharmaceuticals, to treat various diseases is also fueling market growth. As the market witnesses the surge in demand for biopharmaceuticals, the biotechnology contract manufacturing requirements will rise further, in turn, expanding the market growth. Manufacturers are constantly working on new launches and service expansions to better cater to the market needs.

For instance, in July 2023, Kincell Bio, a CDMO specializing in cell therapies, was officially launched with USD 36 million in funding led by Kineticos Ventures. Kincell is a spinoff of Inceptor Bio's CMC, manufacturing, and quality organizations. With its new funding, Kincell plans to accelerate innovative research and clinical trials. The company has acquired a facility and a team in Gainesville, Florida, and intends to expand in other key markets such as Research Triangle Park, Boston, and other customer locations.

Advancements in Manufacturing Technologies

Manufacturing technologies are driving changes in biotech contract manufacturing, leading to improved efficiency, increased customization, and enhanced communication. Automation, flexibility, and supply chain management enhancements have made the manufacturing process more efficient, cost-effective, and reliable. These advancements enable contract manufacturers to produce high-quality products in large quantities, meeting the growing market demand. The growing advancements in personalized medicines and biosimilars further enhance the market traction. For instance, in November 2023, SwiftPharma, a Belgian biotech company specializing in molecular farming, and PlantForm Corporation, a Canadian biopharmaceutical company, entered into a contract manufacturing agreement. Under this agreement, SwiftPharma will manufacture antibodies and proteins for PlantForm's product pipeline. Notably, PlantForm will have non-exclusive access to SwiftPharma's manufacturing expertise, enabling the production of biosimilar pembrolizumab utilizing PlantForm's unique systems and materials.

Dominance of Mammalian-based Platforms

Mammalian cell-based biotechnology creates high-quality proteins that are essential in treating immunological disorders. These products are key in developing antibody treatments for diseases and offer advantages over older methods, such as increased precision and fewer adverse effects. There is a regulatory shift towards replacing animal components in cell growth media used for mammal-derived biotech products. For instance, in May 2023, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This noteworthy achievement enhances Northway Biotech's reputation as a major force in the field of biopharmaceuticals. The successful 2020 opening of Northway Biotech's process and analytical development laboratories in Waltham, Massachusetts, is the reason for this latest expansion. Modern cGMP suites are now part of the new facility, which is a major turning point in the company's history.

Monoclonal Antibodies Segment Dominates the Market

The demand for monoclonal antibodies has increased significantly, especially during the COVID-19 pandemic, leading to challenges in manufacturing capacity and global shortages of raw materials. To meet this demand, biopharmaceutical companies had to innovate by forming strategic partnerships with contract manufacturing organizations, securing raw materials in advance and collaborating closely with health authorities and government agencies. The demand for these antibodies continues to rise, leading to innovations in manufacturing practices to meet global needs. For instance, in September 2023, KBI Biopharma, a subsidiary of JSR Life Sciences, introduced SUREmAb. This optimized solution uses the SUREtechnology Platform to produce monoclonal antibodies (mAbs) more efficiently and cost-effectively. By utilizing SUREmAb, biopharmaceutical manufacturers can expedite their development timelines. It enables the creation of a research cell bank (RCB) in nine weeks. Additionally, customers can swiftly transition from DNA to GMP drug substance in as little as eleven months. SUREmAb is designed to attain titers of up to 10 g/L, resulting in lower-cost workflow, enhanced operational efficiency, and improved return on investment.

North America to be the Dominating Region

North America leads the biotechnology contract manufacturing due to several factors. The region has a strong pharmaceutical and biotech industry and the presence of highly advanced manufacturing technologies, making it an attractive market for contract manufacturing. Additionally, the rising demand for biologics and biosimilars, increasing outsourcing of biologics manufacturing among biopharmaceutical companies, growing focus on personalized medicines, increasing collaborations between pharmaceutical companies and biologics contract manufacturers, and advancements in manufacturing technologies are driving the growth of the biotechnology contract manufacturing market in North America.

For instance, in January 2024, Enzene Biosciences established its first fabrication facility in the United States, positioned in Hopewell, New Jersey. Scheduled for completion in June 2024, the site has already gained interest from customers, who have started reserving capacities for constant production. The facility, developed to incorporate Enzene Biosciences' patented EnzeneX persistent production technology, is located within the Princeton West Innovation Campus, a strategic area surrounded by biotech and pharmaceutical companies. This location is ideal, enabling Enzene Biosciences to cater to budding US biotechnology firms seeking expertise in continuous manufacturing.

Future Market Scenario

The biopharmaceutical industry has already adjusted its partnerships with suppliers and contract development and manufacturing organizations (CDMOs) to satisfy humanitarian requirements, and this pattern is anticipated to grow. There will be more collaborations between CMOs, biotech startups, and pharmaceutical giants, which will create a strong ecosystem that can speed up the delivery of life-saving treatments to patients worldwide. Additionally, the future of contract manufacturing in the pharmaceutical industry will likely see pharmaceutical companies and CDMOs working more closely together, sharing expertise, resources, and risks to come up with more innovative and effective solutions.

In October 2023, Advent International and Warburg Pincus, prominent global investors, finalized the previously announced acquisition of Baxter International Inc.'s BioPharma Solutions (BPS) business. Operating as an independent contract development and manufacturing organization (CDMO) under the name Simtra BioPharma Solutions, the business will maintain its current range of solutions and capabilities to ensure the continued supply of essential pharmaceutical products worldwide. According to the definitive agreement, Baxter received USD 4.25 billion in cash after factoring in closing adjustments.

Key Players Landscape and Outlook

Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), and Baxter Pharmaceutical Solutions LLC are some of the renowned players in the biotechnology contract manufacturing market. These companies play a crucial role in offering specialized services for the manufacturing of biological drugs, particularly biologics, drug substance, and drug product, catering to the needs of pharmaceutical and biotechnological companies globally.

In February 2024, Novo Holdings, a subsidiary of Novo Nordisk, plans to purchase Catalent, a well-established contract manufacturing organization, for USD 16.5 billion. The acquisition will involve Novo Holdings paying USD 63.50 in cash for each outstanding share of Catalent, reflecting a 16.5% increase above the current market value. The transaction is projected to be finalized around the end of 2024.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Biotechnology Contract Manufacturing Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2.By Platform Type
  • 4.2.1.Mammalian-based
  • 4.2.2.Microbial-based
• 4.3.By Product Type
  • 4.3.1.Monoclonal Antibodies
  • 4.3.2.Recombinant Protein
  • 4.3.3.Vaccine
  • 4.3.4.Insulin
  • 4.3.5.Growth factor
  • 4.3.6.Interferons
  • 4.3.7.Others
• 4.4.By Application Type
  • 4.4.1.Clinical
  • 4.4.2.Commercial
• 4.5.By Therapeutic Area Type
  • 4.5.1.Autoimmune Diseases
  • 4.5.2.Oncology
  • 4.5.3.Metabolic Diseases
  • 4.5.4.Ophthalmology
  • 4.5.5.Cardiovascular Diseases
  • 4.5.6.Infectious Diseases
  • 4.5.7.Neurology
  • 4.5.8.Respiratory Disorders
  • 4.5.9.Others
• 4.6.By Region
  • 4.6.1.North America
  • 4.6.2.Europe
  • 4.6.3.Asia-Pacific
  • 4.6.4.South America
  • 4.6.5.Middle East and Africa
• 4.7.By Company Market Share (%), 2023

5.Global Biotechnology Contract Manufacturing Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Platform Type
    • 5.1.2.1.Mammalian-based
    • 5.1.2.2.Microbial-based
  • 5.1.3.By Product Type
    • 5.1.3.1.Monoclonal Antibodies
    • 5.1.3.2.Recombinant Protein
    • 5.1.3.3.Vaccine
    • 5.1.3.4.Insulin
    • 5.1.3.5.Growth factor
    • 5.1.3.6.Interferons
    • 5.1.3.7.Others
  • 5.1.4.By Application Type
    • 5.1.4.1.Clinical
    • 5.1.4.2.Commercial
  • 5.1.5.By Therapeutic Area Type
    • 5.1.5.1.Autoimmune Diseases
    • 5.1.5.2.Oncology
    • 5.1.5.3.Metabolic Diseases
    • 5.1.5.4.Ophthalmology
    • 5.1.5.5.Cardiovascular Diseases
    • 5.1.5.6.Infectious Diseases
    • 5.1.5.7.Neurology
    • 5.1.5.8.Respiratory Disorders
    • 5.1.5.9.Others
  • 5.1.6.United States*
    • 5.1.6.1.Market Size & Forecast
    • 5.1.6.1.1.By Value
    • 5.1.6.1.2.By Volume
    • 5.1.6.2.By Platform Type
    • 5.1.6.2.1.Mammalian-based
    • 5.1.6.2.2.Microbial-based
    • 5.1.6.3.By Product Type
    • 5.1.6.3.1.Monoclonal Antibodies
    • 5.1.6.3.2.Recombinant Protein
    • 5.1.6.3.3.Vaccine
    • 5.1.6.3.4.Insulin
    • 5.1.6.3.5.Growth factor
    • 5.1.6.3.6.Interferons
    • 5.1.6.3.7.Others
    • 5.1.6.4.By Application Type
    • 5.1.6.4.1.Clinical
    • 5.1.6.4.2.Commercial
    • 5.1.6.5.By Therapeutic Area Type
    • 5.1.6.5.1.Autoimmune Diseases
    • 5.1.6.5.2.Oncology
    • 5.1.6.5.3.Metabolic Diseases
    • 5.1.6.5.4.Ophthalmology
    • 5.1.6.5.5.Cardiovascular Diseases
    • 5.1.6.5.6.Infectious Diseases
    • 5.1.6.5.7.Neurology
    • 5.1.6.5.8.Respiratory Disorders
    • 5.1.6.5.9.Others
  • 5.1.7.Canada
  • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Platform Type
• 6.2.By Product Type
• 6.3.By Application Type
• 6.4.By Therapeutic Area Type
• 6.5.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Patent Landscape
• 9.2.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Catalent Inc.
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Lonza Group Ag
• 13.3.Patheon N.V. (Thermo Fisher Scientific Inc.)
• 13.4.Abzena Plc.
• 13.5.Sandoz International GmbH (Novartis AG)
• 13.6.Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
• 13.7.Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
• 13.8.AbbVie Contract Manufacturing (AbbVie Inc.)
• 13.9.Samsung Biologics Co. Ltd.
• 13.10.Pfizer Centre Source Ltd (Pfizer Inc.)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer